Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Tunisia has been steadily developing in recent years, with increasing demand for cancer treatments and a growing focus on healthcare in the country.
Customer preferences: Tunisian customers in the Oncology Drugs market are looking for effective and affordable treatments for cancer, with a preference for drugs that have been approved by international regulatory bodies. They also prioritize drugs with minimal side effects and a high success rate in treating various types of cancer.
Trends in the market: One of the key trends in the Oncology Drugs market in Tunisia is the increasing availability of generic drugs, which has led to greater affordability and accessibility for patients. Additionally, there has been a growing focus on research and development of new cancer treatments in the country, with several local companies investing in this area. Another trend is the increasing use of immunotherapy in cancer treatment, which has shown promising results in clinical trials.
Local special circumstances: Tunisia has a relatively high incidence of cancer, with lung cancer being the most common type in men and breast cancer in women. This has led to a greater demand for cancer treatments in the country. Additionally, the government has been taking steps to improve healthcare infrastructure and increase access to treatments, which has further boosted the Oncology Drugs market.
Underlying macroeconomic factors: The Tunisian economy has been growing steadily in recent years, with a focus on sectors such as healthcare and pharmaceuticals. This has led to greater investment in research and development of new treatments and increased availability of drugs in the market. Additionally, the country has a young and growing population, which has contributed to a rising demand for healthcare services. However, there are also challenges such as a lack of healthcare funding and limited access to advanced treatments in certain regions of the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
